natgillin/translations-raw huggingface dataset:
The method according to claim 1, characterized in that said step for constructing an upper shoe assembly comprises the association of said upper membrane (14) with said lining (12), so as to not compromise their vapor permeability, such as by spot gluing, lamination or the like. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se navedena faza izrade gornjišta cipele sastoji od spajanje navedene membrane gornjišta (14) s navedenom postavom (12), na način da se ne ugrožava njihovo svojstvo paropropusnosti, primjerice točkastim lijepljenjem, laminacijom ili sličnim postupkom.
Antibody-Drug conjugate obtainable by the process according to claim 12. Process for the preparation of a modified antibody, the process comprising: 
Postupak za pripremu modificiranog antitijela, naznačen time što postupak sadrži:
The compound for use of claim 5, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R7 is methyl; or wherein Rd is -C(O)-(C1-C6)alkyl; or wherein Rd is -C(O)-CH2-O-(C1-C6)alkyl. 
Spoj u skladu s patentnim zahtjevom 4, ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer, naznačen time što Rd je -C(O)-(C1-C6)alkil; ili što Rd je -C(O)-CH2-O-(C1-C6)alkil.
The isolated CD133+ BMDSC for use according to claim 1, wherein the subject has endometrial atrophy that is resistant to hormonal treatment. 
Izolirane CD133* BMDSC za uporabu prema patentnom zahtjevu 1, naznačene time što subjekt ima atrofiju endometrija koja je rezistentna na hormonsko liječenje.
In a further embodiment, the present invention also relates to use of a compound of formula I for the preparation of a medicament for the treatment of obsessive compulsive disorder. 
U daljnjoj verziji, ovaj izum se odnosi i na uporabu spoja formule I za pripravu lijeka za liječenje opsesivno kompulzivnog poremećaja.
An antibody that binds to human CD37 and has a heavy chain comprising the amino acid sequence of SEQ ID NO:36 and preferably a light chain comprising the amino acid sequence of SEQ ID NO:38. 
Protutijelo, naznačeno time, da se veže na ljudski CD37 i ima jaki lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:28 i slabi lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:30.
1 is a longitudinally sectioned view of a jar according to the invention; 
Slika 1 - predstavlja uzdužni presjek udaraca prema izumu;
An apparatus for generating hydroxyl radicals comprising a base unit (200) and a consumable cartridge (100) in accordance with any preceding claim, the base unit comprising a means for providing electrical power (232, 234) to the consumable cartridge, and a means for driving air (220) through the apparatus. 
Uređaj za stvaranje hidroksilnih radikala naznačen time da sadrži osnovnu jedinicu (200) i potrošni uložak (100) u skladu s bilo kojim od prethodnih zahtjeva, te osnovna jedinicu sadrži sredstva za stvaranje električne energije (232, 234) za potrošni uložak, i sredstva za pokretanje zraka (220) kroz uređaj.
Objects and Advantages of the Invention:- 
Broj objave europskog patenta:
Accordingly, in some embodiments, the species specific target DNA sequence is amplified by a set of primers and the resulting amplicon is detected by a labelled hybridisation probe, the primers and probes being selected from the following: 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da je metagenomska ciljna DNK. sekvenca sekvencirana postupkom za masivno paralelno sekvenciranje; i opcionalno naznačeno time da je postupak za masivno paralelno sekvenciranje odabran od sekvenciranja emulzije, i sekvenciranja krute faze.
and the second polypeptide chain comprises an amino terminus and a carboxy terminus and from N-terminus to C-terminus: 
(ID) navedeni drugi polipeptidni lanac sadrži amino terminus i karboksi terminus i od N-terminusa do C- terminusa:
Also encompassed by the present invention is use of a compound of the present invention, or a pharmaceutically acceptable salt, solvate or hydrate thereof, for the manufacture of a medicament for the treatment of diabetes. 
Ovaj izum također obuhvaća upotrebu spoja prema ovom izumu, ili njegove farmaceutski prihvatljive soli, solvata ili hidrata, u proizvodnji lijeka za liječenje dijabetesa.
X is selected from a group consisting of —CO2R12, and a carboxylic acid isostere; 
je odabran iz skupine koju čine sljedeći: -Ci.palkii, aril, heteroaril, karbociklil i heterociklil; i
R′2 is selected from hydrogen and halo; 
R', je odabran od vodika i halo; 10
means (24, 240, 25, 250, 26, 260, 29, 290) are provided for withdrawing clarified liquid resulting from gravity sedimentation of the slurry from said container (20) at an adjustable level. 
(i) su načinjena sredstva (24, 240, 25, 250, 26, 260, 29, 290) za vađenje izbistrene tekućine koja je dobivena gravitacijskom sedimentacijom od mulja iz navedenog spremnika (20) na podesivoj razini.
A device according to claim 3, wherein the second region has a fourth angle of conicity between 0 degrees and 8 degrees. 
Uređaj prema zahtjevu 4, naznačen time, da drugo područje (14) ima kut koničnosti (22) od 0 stupnjeva do 8 stupnjeva.
The drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects comprises: 1. a reservoir, said reservoir comprising; 2. at least one active ingredient; and, optionally, 3. at least one pharmaceutically acceptable carrier; a polyurethane based polymer completely surrounding the reservoir. 
Uređaj za oslobađanje lijeka za oslobađanje jednog ili više lijekova pri kontroliranim stopama oslobađanja u toku produženog vremenskog perioda da se proizvedu lokalni ili sistemski farmakološki efekti, naznačen time, što navedeni uređaj za oslobađanje lijeka ima: i.
The aqueous pharmaceutical suspension according to claim 3, wherein the sweetener system comprises xylitol and sucrose, and the ratio of the amount of sucrose: xylitol is 2:1. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što sustav sladila sadrži ksilitol i saharozu, a odnos količina saharoza/ksilitol je otprilike 2:1.
Adjacent floor elements 18 are connected to each other by the profiles 19 and are supported on temporary supports. 
Susjedni podni elementi 18 međusobno se spajaju profilima 19a poduprti su privremenim podupiračima. Nakon postavljanja ojačanja
roll forming said races (7) on the outer surface of the body obtained thereby. 
€) valjanje navedenih utora (7) po vanjskoj površini tako dobivenog tijela.
The pharmaceutical combination of claim 37 wherein the second compound is selected from the group consisting of a corticosteroid, hydroxychloroquine, cyclophosphamide, azathioprine, mycophenolate mofetil, methotrexate, janus kinase inhibitor, statin, calcipotriene, infliximab, adalimumab, certolizumab pegol, golimumab and etanercept, cetirizine, loratidine, desloratidine, fexofenadine, astemizole, azelastine, chlorpheniramine, secukinumab, RG-7624, brodalumab, ixekizumab, angiotensin-converting enzyme inhibitor and angiotensin receptor blocker; and an optional pharmaceutically acceptable carrier, excipient or diluents. 
Farmaceutska kombinacija, naznačena time što sadrži terapijski djelotvornu količinu pripravka koji sadrži: prvi spoj, gdje je prvi spoj spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol; drugi spoj, gdje se drugi spoj bira iz skupine koju čine kortikosteroid, hidroksiklorokin, ciklofosfamid, azatioprin, mikofenolat mofetil, metotreksat, inhibitor janus kinaze, statin, kalcipotrien, inhibitor angiotenzin-konvertirajućeg enzima i blokator angiotenzinskog receptora; i izborna farmaceutski prihvatljiva podloga, pomoćna tvar ili razrjeđivači.
The fusion protein of any of claims 1-8 for use in target cell-restricted activation of effector cells expressing IL2/IL-15RBY and/or for use in target cell-restricted target cell killing mediated by effector cells expressing IL-2/IL-15RBY. 
Fuzijski protein u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačen time što je namijenjen upotrebi u aktiviranju efektorskih stanica koje eksprimiraju IL2/IL-15RBY ograničenom na ciljne stanice i/ili što je namijenjen upotrebi u ubijanju ciljnih stanica ograničenom na ciljne stanice, gdje posreduju efektorske stanice koje eksprimiraju IL-2/IL-15RBY.
Several factors affect the rheological properties of the hydrogel, such as the relative amount of monomer used, the relative amount of initiator, the temperature and other parameters of the polymerisation process, and the washing process. 
Nekoliko faktora djeluje na Teološka svojstva hidrogela, takvih faktora kao što je relativna količina monomera koji se koristi, relativna količina inicijatora, temperatura i drugi parametri postupka polimerizacije.
reacting a compound of formula (2a): or a salt thereof, with a sulfonating agent to form a compound of formula (IV): or a salt thereof; and 
reakciju spoja formule (2a): ili njegove soli, sa sredstvom za sulfoniranje, da se dobije spoj formule (IV): ili njegova sol;
Depth of engraving of the second disc µm 
Dubina ureza drugog diska:
According to a preferred embodiment, the lipophilic medium is fish oil or cod liver oil. Said oils can be purchased in a purified form and enriched in Omega 3 in particular in EPA and DHA. Fish oil or cod liver oil contain polyunsaturated fatty acids, called Omega 3, including EPA and DHA. 
Sastav prema patentnim zahtjevima od 1 do 3, naznačen time, da se navedeni lipofilni medij odabire između ribljeg ulja ili ulja jetre bakalara. Sastav prema patentnom zahtjevu 5, naznačen time, da se navedeni lipofilni medij odabire između ribljeg ulja ili ulja jetre bakalara u pročišćenom obliku i obogaćenom u odnosu na Omega 3.
a nonionic surfactant which is a C10-C16 ethoxylated alcohol in a quantity higher than 0.1% by weight with respect to the total weight of the additive composition with integrated action, preferably in a quantity ranging from 0.1% to 5% by weight; 
neionskog surfaktanta koji je C10-C16 etoksilirani alkohol u količini većoj od 0.1% masenih u odnosu na ukupnu masu kompozicije aditiva sa integriranim djelovanjem;
The optical assembly according to claim 1, wherein said primary optical system is partitioned into a plurality of areas, each one corresponding to a respective primary focus and/or secondary reflector element. 
Optički sklop u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da je navedeni primarni optički sustav (2) podijeljen u više područja (211-242), a svaki od njih odgovara primarnom fokusu (Fl-i) i / ili sekundarnom reflektorskom elementu (31-38).
The binding moiety of claim 1, wherein the binding moiety binds to at least one amino acid of the amino acid sequence X2ETCEX3R (SEQ ID NO: 20), wherein X2 and X3 are defined as in claim 1. 
Vezujuća grupa prema zahtjevu 1, pri čemu se vezujuća grupa vezuje za najmanje jednu aminokiselinu aminokiselinske sekvence s DETCEQR (SEQ ID NO: 4).
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS OF THE INVENTION 
Datum podnošenja europske prijave patenta:
The panel according to claim 1, wherein the second locking element is positioned at a distance from an upper side of the downward groove and/or wherein the second locking element is positioned at a distance from an lower side of the downward groove. 
Panel (1, 42, 43, 46, 53, 57) prema jednom od prethodnih patentnih zahtjeva, pri čemu je drugi element (30, 69) za zaključavanje izveden na udaljenosti od gornje stranice prema dole usmjerenog žlijeba (27, 68).
The compound according to claim 1 or 2, characterized in that X3 can be a σ bond, a divalent alkyl chain containing from 1 to 3 carbon atoms, a divalent alkanoyl chain of the type -CO-(CH2)1-2-, wherein the hydrogen atoms of said alkyl and alkanoyl chains can be optionally substituted with one or more halogen atoms, or one or more C1-3alkyl groups. 
Spoj prema zahtjevu 1, naznačen time, da X. može biti karbonil-skupina, divalentni alkil-lanac koji sadrži od 1 do 3 atoma ugljika, divalentni alkanoil-lanac tipa ili tipa (CH>),3-CO-, pri čemu atomi vodika od navedenih alkil-lanca i alkanoil-lanca, mogu biti opcijski supstituirani s jednim ili više atoma halogena, ili s jednom ili više Ci3alkil-skupina.
Process as claimed in claim 7, wherein the reinforcing material is a non-woven polyester. Waterproofing membranes obtainable by the process claimed in claim 8. 
Postupak kako je prijavljen u patentnom zahtjevu 7, naznačen time da je materijal za pojačavanje netkani poliester.
The hydrophobised ground calcium carbonate and/or the hydrophobised precipitated calcium carbonate according to any one of the claims 20 to 25, wherein the hydrophobised ground calcium carbonate and/or the hydrophobised precipitated calcium carbonate is in powder form and/or in the form of granules or in the form of slurry. 
Hidrofobirani prirodni kalcijev karbonat i/ili hidrofobirani taložni kalcijev karbonat prema bilo kojem od zahtjeva 17 do 21, naznačen time da je hidrofobirani prirodni kalcijev karbonat i/ili hidrofobirani taložni kalcijev karbonat u praškastom obliku i/ili u obliku granula ili u obliku suspenzije.
The controls (vehicle and Rapamycin at 2.5 mg/kg/day) or 42-0-(D-Fructosylearbonyl)rapamycin, at 2.5 and 10 mg/kg/day were administered once daily by oral gavage to the transplant recipients (6 rats per group) starting 3 days prior to transplantation and continuing for 30 days post-transplantation. 
Kontrola (nosač i rapamicin u dozi od 2,5 mg/kg/dan) ili 42-0-(D- fruktozilkarbonil)rapamicin u dozi od 2,5 i 10 mg/kg/dan primjenjivani su jednom dnevno oralnim putem primateljima transplantata (6 štakora po grupi), počevši 3 dana prije transplantacije i nastavljajući 30 dana nakon transplantacije.
The biologically active protein according to any one of claims 1 to 5, wherein said polypeptide with biological activity is selected from the group consisting of binding molecules, antibody fragments, cytokines, growth factors, hormones or enzymes. 
Biološki aktivni protein u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što se navedeni polipeptid s biološkom aktivnošću bira iz skupine koju čine vežuće molekule, fragmenti protutijela, citokini, čimbenici rasta, hormoni ili enzimi.
The siRNA according to any one of claims 1 to 4, wherein 1 to 10 consecutive nucleotides excluding an overhang nucleotide from the 3' terminus of the sense strand of the siRNA are converted into DNA and 1 to 10 consecutive nucleotides from the 5' terminus of the antisense strand of the siRNA are converted into DNA. 
SIRNA u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time, da se 1 do 10 uzastopnih nukleotida s iznimkom izbočenog nukleotida iz 3' terminusa sens lanca siRNA pretvaraju u DNA 1 da se 1 do 10 uzastopnih nukleotida iz 5' terminusa antisens lanca siRNA pretvaraju u DNA.
was charged to the insert followed by 8.4µL (0.413µmol, 0.1 eq.) 
bilo je stavljeno u kivetu i nakon toga 8.4 uL (0.413 mol, 0.1 ekv.)
Thus the applicants have found that a dose of, or dose equivalent to, 6 to 18 µg, for example 9 to 14 µg, for example 12 µg, human derived recombinant FSH is suitable for use in the treatment of infertility in a patient having serum AMH <15 pmol/L, for example 0.05-14.9 pmol/L for example 5.0-14.9 pmol/L. The dose provides an effective response while minimising risk of OHSS. 
HR P20191437 T1 PATENTNI ZAHTJEVI Proizvod koji sadrži rekombinantni ljudski folikulostimulirajući hormon (FSH) za upotrebu u liječenju neplodnosti kod pacijenta koji ima razinu serum AMH <15 pmol/L, naznačen time da se proizvod daje u dozi od, ili ekvivalentnoj 11-13 ug rekombinantnog ljudskog FSH na dan, 12 do 16 dana nakon primjene GnRH agonista.
The monoclonal antibody or antigen binding fragment thereof of claim 1 which binds to at least four CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, CCL14/HCC-1, and CCL18/PARC, and which does not bind to CCL2/MCP-1. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje četiri CC kemokina odabranih iz skupine koja se sastoji od CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, CCL14/HCC-1, i CCL18/PARC, i koji se ne vežu na CCL2/MCP-1.
preparation of perfluoro-4-methyl-2-pentene (intermediate (2)) in a Step 1 by reacting hexafluoropropene (compound (1)) in the presence of a catalyst to form its dimer perfluoro-4-methyl-2-pentene; and 
pripravu perfluoro-4-metil-2-pentena (intermedijer (2)) u Koraku 1 reakcijom heksafluoropropena (spoj (1)) u prisutnosti katalizatora da bi nastao njegov dimer perfluoro-4-metil-2-penten; i
Circulation through the homogenizer is advantageous because it can reduce the average size of the oil droplets in the first emulsion. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da je prosječna veličina uljne kapljice nakon filtracije manja od 220 nm.
As an alternative, it is possible to provide the shoe 200, as described in the previous examples, by providing part of the sole 211 by overmolding on the assembly 212. 
Kao alternativa, moguće je izraditi cipelu 200, kako je opisano u prethodnim primjerima, izradom dijela potplata 211 prešanjem preko ruba na sklop 212.
The product could be crystallised from methanol, acetone or ethyl acetate. 
Proizvod se može prekristalizirati iz metanola, acetona i etilacetata.
A process according to claim 33 wherein the coupling agent is 1,1'-carbonyldiimidazole (CDI) or 1-(3-dimethylaminopropyl)-ethylcarbodiimide hydrochloride (EDCI). 
Postupak u skladu s patentnim zahtjevom 33, naznačen time što je kondenzacijsko sredstvo 1,1'- karbonildiimidazol (CDI) 1li 1-(3-dimetilaminopropiljetilkarbodiimid-hidroklorid (EDCI).
In another preferred embodiment, following the addition of said 2-aminoethanol, the change of suspension conductivity in uS/cm/pH unit is maintained at a value within 10%, preferably within 6%, and more preferably within 3%, of the suspension conductivity value prior to 2-aminoethanol addition. 
Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time što se nakon dodavanja 2-aminoetanola promjena provodljivosti suspenzije u uS/ecm/pH jedinica održava pri vrijednosti unutar 10 %, poželjno unutar 6 %, i poželjnije unutar 3 %, vrijednosti provodljivosti suspenzije prije dodavanja 2-aminoetanola.
The epoxide (VII) is then subjected to a reductive ring opening using borane-THF as an electrophilic reducing agent to give an intermediate borane complex (not shown) which is then oxidised and cleaved with hydrogen peroxide in the presence of an alkali such as sodium hydroxide to give a dihydrotetrabenazine (VIII) as a mixture of the 2 R,3 S,11b R and 2 S,3 R,11b S isomers, of which only the 2 R,3 S,11b R is shown for simplicity. 
Epoksid (VII) se zatim podvrgne reduktivnom otvaranju prstena uporabom boran-THF kao elektrofilnog reducirajućeg sredstva da bi se dobio intermedijerni boran kompleks (nije prikazan) koji se zatim oksidira i cijepa s vodikovim peroksidom u prisutnosti lužine poput natrij hidroksida da bi se dobio dihidrotetrabenazin (VIII) kao smjesa 2R,35, 11bR i 25,3R, 11bS izomera, od kojih je prikazan jedino 2R,3S,11bR radi jednostavnosti.
A compound of claim 1 as used in claim 13, wherein the disease is psoriasis. 
Spoj prema zahtjevu 1 za upotrebu prema zahtjevu 13, naznačen time da je bolest psorijaza.
wherein the sending the first power headroom report comprises: 
prije slanja prvog izvješća o zadržanoj snazi, postupak dodatno sadrži:
Contacting the fixated cells resulting from step c. with a hybridization probe directed to a nucleic acid comprising at least 10 bp of a CD146 gene differentially expressed in fetal cells of a maternal blood sample, or 
hibridizacijskom sondom usmjerenom prema nekoj nukleinskoj kiselini koja sadrži najmanje 10 bp (baznih parova) gena koji je diferencijalno izražen u fetalnim stanicama uzorka majčine krvi, naznačeno time da je taj gen TMEFF2 ili
The pharmaceutical composition of claim 15, wherein the therapeutic agent is a fast-acting insulin that is a regular insulin or is an insulin analog. A pharmaceutical composition of any of claims 14-18 for use in treating a hyaluronan-associated disease or disorder, or for use in treating diabetes, or for use in delivering a therapeutic agent to a subject. 
Farmaceutska kompozicija prema patentnom zahtjevu 16 za isporuku terapeutskog sredstva za uporabu u liječenju tumora; za uporabu u liječenju akumulacije glikozaminoglikana u mozgu; za uporabu u liječenju kardiovaskularnog poremećaja; za uporabu u liječenju oftalmičkog poremećaja; ili za uporabu u liječenju plućne bolesti.
Use of an amount of an opioid antagonist in an amount at least sufficient to substantially antagonize a therapeutic amount of opioid agonist when both, the opioid agonist and the opioid antagonist, are administered intravenous at the same time, in the form of a controlled release dosage form comprising a homogeneous controlled release matrix formulation comprising a hydrophobic material, including at least one hydrophobic polymer and at least one fatty alcohol or fatty acid, and said therapeutic amount of an opioid agonist and said sufficient amount of opioid antagonist, to prevent the formation of an extract of said controlled release matrix formulation comprising the opioid agonist by a one step extraction procedure comprising the steps of: 
Uporaba količine opioidnog antagonista koja je dovoljna da barem bitno djeluje antagonistički na terapijsku količinu opioidnog agonista kada se oba, opioidni agonist 1 opioidni antagonist, daju istodobno intravenski kao dozirni oblik s kontroliranim oslobađanjem koji sadrži homogenu formulaciju matriksa s kontroliranim oslobađanjem, a koja sadrži hidrofobni materijal, uključujući barem jedan hidrofobni polimer, gdje je hidrofobni polimer etil celuloza i barem jedan masni alkohol ili masnu kiselinu izabrane između C;> do C34 alifatskih alkohola ili kiselina, i terapijsku količinu opioidnog agonista i dovoljnu količinu opioidnog antagonista, da se spriječi nastanak ekstrakta formulacije matriksa s kontroliranim oslobađanjem koja sadrži opioidni agonist pomoću postupka ekstrakcije u jednom koraku, a postupak obuhvaća korake:
% (1 grade improvement) % (worsened) dystrophy 
3% (poboljšanje 1. stupnja) 3% (poboljšanje 2. stupnja)
Thus, there is also a need in the design of a jar for a more effective arrangement for securing the components together before their intended separation. 
To znači da postoji potreba 1 za takvom konstrukcijom udaraca koja će biti učinkovitija u međusobnom osiguravanju komponenata prije njihovog predvidenog odvajanja.
is H, R7, or substituted or unsubstituted aryl or heteroaryl; Q is chosen from wherein R8 is hydrogen, halogen, or C1-6 alkyl and * indicates attachment points; 
Ru je H, Ry, ili supstituirani ili nesupstituirani aril ili heteroaril; Q) je izabran iz pri čemu je Rg vodik, halogen, ili C,.galkil 1 * označava točke spajanja;
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to any one of clauses 1-119. 
Farmaceutski pripravak, naznačen time, da sadrži farmaceutski prihvatljiv nosač 1 farmaceutski učinkovitu količinu spoja u skladu s bilo kojim od patentnih zahtjeva 1-13.
correlating the presence or absence of the immunological complex with the presence or absence of amyloid protein in the specific body part or body area; and 
koreliranja prisutnosti ili odsutnosti imunološkog kompleksa s prisutnošću ili odsutnošću amiloidnog proteina u uzorku; i
Measurement of the Modulation of ERK activation 
Broj objave europskog patenta:
The solid was washed with pentane (3x30mL) and dried under vacuum at RT to give a white powder (m=8.51g). 
Krutina se ispere s pentanom (3 x 30 mL) i osuši pod vakuumom pri sobnoj temperaturi da se dobije bijeli prah (m = 8,51 g).